Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.41 |
| ▸ | RXRA | P19793 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14068810 | 0.84 | GPR119 (0.48) | RIPK1GPR119NR1H2NR1H3RXRA | |
| SCHEMBL451784 | 0.82 | RIPK1 (0.47) | RIPK1GPR119NR1H2NR1H3RXRA | |
| SCHEMBL451785 | 0.82 | RIPK1 (0.47) | RIPK1GPR119NR1H2NR1H3RXRA | |
| SCHEMBL17067869 | 0.81 | RIPK1 (0.73) | RIPK1NR1H2NR1H3 | |
| SCHEMBL469686 | 0.81 | RIPK1 (0.73) | RIPK1NR1H2NR1H3 | |
| SCHEMBL17067870 | 0.81 | RIPK1 (0.73) | RIPK1NR1H2NR1H3 | |
| SCHEMBL15185124 | 0.80 | RIPK1 (0.49) | RIPK1GPR119NR1H2NR1H3RXRA | |
| SCHEMBL15185072 | 0.80 | RIPK1 (0.49) | RIPK1GPR119NR1H2NR1H3TP53 | |
| SCHEMBL15185129 | 0.80 | RIPK1 (0.52) | RIPK1GPR119MEN1KMT2AGRM5 | |
| SCHEMBL29116144 | 0.79 | RIPK1 (0.54) | RIPK1GPR119NR1H2NR1H3RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637516-B2 | Compounds and compositions as TRK inhibitors | IRM LLC (BM) | 2014-01-28 | — | — | US | disclosed |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | TNK2, CNKSR1, BMP2K | RIPK1 168/4885GPR119 790/4885NR1H2 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.